

Yousef M. Shehata<sup>1</sup>, Youstri M Hussein<sup>2</sup>, Aaser M. Abdelazim<sup>1</sup>, Rasha L. Etewa<sup>2</sup>, Mohamed H. Alhady<sup>3</sup>

<sup>1</sup>Biochemistry Department, Faculty of Veterinary Medicine Zagazig University, Egypt.

<sup>2</sup>Medical Biochemistry Department Faculty of Medicine, Zagazig University, Egypt.

<sup>3</sup>Horticulture Department, Faculty of Agriculture, Zagazig University, Egypt.

(Received October 10<sup>th</sup>, 2010 Revised November 16<sup>th</sup>, 2010 Accepted November 23<sup>rd</sup>, 2010 Published online December 22<sup>nd</sup>, 2010.)

**Correspondence:** Aaser Mohamed Abdelazim  
Email: [drasr\\_bio@yahoo.com](mailto:drasr_bio@yahoo.com)

## Hypoglycemic Effect Of Button (*Agaricus Bisporus*) And Oyster (*Pleurotus Ostreatus*) Mushrooms On Streptozotocin Induced Diabetic Mice

In the present study, we examined the hypoglycemic effect of two species of edible mushrooms which are widely cultivated in Egypt. Fifty-six male Swiss mice of average weight 25±5 grams were used in the study. Mice were randomly divided into two main groups. Group A that served as control did not receive any treatment and group B was streptozotocin (STZ)-induced diabetic group. The latter was divided into three subgroups, B1 diabetic–insulin treated, B2 diabetic–oyster and B3 diabetic–button agaricus. Blood glucose levels were routinely determined every week. After 30 and 60 days, mice from all groups were sacrificed. Blood samples and livers were collected for determination of hepatic glycogen, hepatic glucokinase activity and mRNA expression levels of GK. Our results revealed a significant hypoglycemic effect of the two species of mushrooms. There was a significant change in the hepatic glycogen content with a marked increase in the expression level of GK in mushroom feeding groups. We can conclude that Oyster and Button mushrooms have a potent hypoglycemic effect on diabetic mice which gives us a new prospect to face diabetes mellitus with high effect and low cost.

**Key words:** button, oyster, mushroom, glucokinase, glycogen, blood glucose, diabetes

## INTRODUCTION

Currently, there is no perfect approach to treat diabetes as a common metabolic disorder [1]. Diet supplemented with fruit and vegetables had beneficial effects on diabetes [2]. Mushrooms are a nutritional goldmine and are one of nature's greatest providers of completely natural health benefits without toxicity [3]. White mushrooms contain high levels of dietary fibers and antioxidants; beta glycan; folate; ergothioneine; and polyphenols, [4-7] suggesting that the mushrooms may have potential hypoglycemic effects and may provide beneficial effects on Diabetes Mellitus. Mushrooms that are rich in trace elements were reported to lower blood glucose and increase glycogen [8, 9]. *Agaricus bisporus* can lower the blood glucose in STZ-induced diabetic rats [1]. Glucokinase (GK) is the principal determinant of both hepatic and islet glucose utilization [10]. It promotes glycogen synthesis in the liver [11]. Low GK activity would cause diabetes, even though GK activity has long been thought to be a key determinant of hepatic glucose usage [12]. GK activators with optimized properties would be able to both blunt the postprandial glucose excursion and lower the fasting blood glucose in DM patients [11]. Few studies were performed on the possible hypoglycemic effect of oyster mushrooms which have been cultivated and produced extensively in Egypt and developing countries. The aim of this study was to clarify the hypoglycemic mechanism of Oyster and Button mushrooms through studying GK activity, its gene expression, hepatic glycogen content in normal and diabetic mice in comparison with insulin treatment in a trial to provide pre-clinical data of the effectiveness of mushrooms as GK activator. This represents a promising and new control option for DM.

## MATERIALS AND METHODS

### Protocol

Fifty-six male Swiss mice of average age 4-5 months and weighted at the beginning of the experiment (25±3 grams), were housed in groups of seven in stainless steel cages in a room with a temperature of 22°C ± 2°C, a relative humidity

of 55% ± 5%, with a light-dark phase of 12 hours with free access to basal diets and water.

### Induction of diabetes and animal diets

After acclimatization for 7 days, fourteen mice served as control group (group-A) and they were fed on base diet. The remaining mice were fasted for 12 hours before intraperitoneal administration of single dose of STZ (Sigma Chemical Co., Poole, Dorset, UK) at 100 mg/kg body weight in 0.01 M sodium citrate buffer (pH 4.5) [13]. Two days after STZ treatment, the mice were considered diabetic (B), as determined by non-fasting blood glucose levels of >200 mg/dL [14]. The diabetic group were sub-classified into 3 subgroups; 1, 2 and 3. sub-group B1(n=14): were treated by insulin (0.3 units/ 50 gm body weight dissolved in 0.5 ml physiological saline according to Lee et al., [15]; sub-group B2 (n=14): were fed on Oyster mushroom (*Pleurotus ostreatus*); sub-group B3(n=14): were fed on Button mushroom (*Agaricus bisporus*). All animals were sacrificed after 30 and 60 days. The fresh fruiting bodies of *P. ostreatus* and *A. bisporus* were subjected to drying at a temperature of 55-60 °C until complete dehydration [16]. Mushrooms were incorporated into the diet by dose of 62.5 g/kg [17].

### Blood glucose

Blood glucose was detected using one touch glucose strip (USA).

### Blood and tissue sampling

Liver samples for RNA extraction were collected and preserved in liquid nitrogen until the RNA extraction. Samples for biochemical examinations were homogenized in physiological saline, none immediately examined samples were preserved at -20 until further investigations.

### Biochemical Analysis

Hepatic glycogen contents were determined according to Roehring & Allred [19] and hepatic glucokinase activity was measured using the method of Pakoske et al., [20].

### Molecular Analysis

Total RNA was extracted from liver tissues using an RNA extraction solution (ISOGEN; Nippon Gene, Tokyo, Japan) according to the manufacturer's protocol.

#### Glucokinase enzyme expression level determination

The expression level of glucokinase (GK) enzyme in mice livers was determined by Reverse transcriptase polymerase chain reaction (RT-PCR) [21].

First strand cDNA was synthesized using two steps Superscript II kit (Invitrogen, Carlsbad, CA). The amplification was performed using thermal cycler (Takara MP, Japan) with cycling conditions of 25 °C for 10 min (denaturation), 42 °C for 90 min (annealing), 95 °C for 3 min (extension) and chilled in ice for 5 minutes. RT-PCR was performed using GK specific oligoneucleotide primers pair, and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as housekeeping gene. The primer pairs for amplification were designed as the following, Gk primers, forward, 5'-CAC CCA ACT GCG AAA TCACC-3' and reverse, 5'-CAT TTG TGG GGT GTG GAG TC-3' and for GAPDH, forward, 5'-CCCGTAGACAAAATGGTGAAGGTC-3' and reverse, 5'-GCCAAAGTTGTCATGGATGACC-3' with product sizes, 162 and 215 respectively. Then the amplified PCR products were electrophoresed on 1.5% Agarose gel in 1X Tris acetate EDTA running buffer (1 x TAE) with condition of 100 Voltage/ 40 min as described by Uchida *et al.*, [22].

Statistical analysis: The data was processed using the statistical package for social science (SPSS Inc., Chicago, IL, version 13, USA). All results are expressed as mean  $\pm$  SD. Comparison among groups was made by Student's *t*-test (unpaired), One-way analysis of variance (ANOVA). Duncan's test was used for testing the inter-grouping homogeneity. Statistical significance was set  $P < 0.05$ .

## RESULTS

The effects of mushrooms; Oyster (*Pleurotus ostreatus*), Button (*Agaricus bisporus*) feeding and insulin treatment on fasting blood glucose level (mg/dL), hepatic glycogen content (mg/gm tissue), and hepatic glucokinase activity (U/L) in STZ- induced diabetic mice are summarized in Table I.

#### Blood Glucose level

The blood glucose was significantly lowered in mushrooms feeding groups and insulin treated one compared to the control group ( $P < 0.05$ ) (Figure 1).

#### Hepatic glycogen content

Our results revealed that the hepatic glycogen contents show variation between groups at the two durations of the experiment. Hepatic glycogen content insignificantly declined after 30 days in diabetic treated groups, while it was shown to be significantly increased in diabetic treated groups after 60 days of the experiment (Table 1).

#### Hepatic glucokinase activity

There was an observed oscillation in the activity of the enzyme, while the activity increased in the second duration of experiment in all diabetic treated groups when compared with their control.

#### Hepatic glucokinase expression

There was a significant increase in the hepatic glucokinase expression level in insulin treated, Oyster and Button treated mice ( $P > 0.05$ ) (Figure 3).

## DISCUSSION

In the present study, we have demonstrated that Oyster and Button mushrooms have significant hypoglycemic effects in diabetic mice. The hypoglycemic effects of Oyster and Button mushrooms were detected as the reduction ratio of fasting blood glucose (FBG) level in control groups to that of the diabetic treated groups with insulin and mushrooms. Different literatures have reviewed the hypoglycemic effects of various types of mushrooms [1, 8, 23, 24]. Compounds in mushrooms such as beta glucans are effective in lowering blood cholesterol levels and glycemic response *in vivo* [25-27, 30]. Although the hepatic glycogen contents showed variation between groups in the two durations of the experiment, hepatic glycogen concentration in insulin treated group increased as high blood glucose level stimulates insulin to activate both hepatic glucokinase and glycogen synthase to increase the rate of glucose uptake by the cell and glycogen synthesis respectively [28]. The level of hepatic glycogen in mushroom fed groups in the first duration of the experiment (30 days) was insignificantly low if compared with their control group in the same duration. We can reveal this is due to the inability of mushrooms to induce significant changes in glycogen content through the first 30 days of experiment. Feeding mushrooms for 30 days may be insufficient to induce changes in hepatic glycogen. Previously, it was shown that 45 days feeding of mushrooms can increase hepatic glycogen contents [9]. The high level of hepatic glycogen in diabetic treated groups in second duration of the experiment was in the same line of Zhou & Han [29]. GK has high control strength on glucose metabolism by glycogen synthesis and glycolysis [10]. Accordingly, small changes in GK activity are associated with correspondingly large changes in glucose metabolism [31]. There are reports of decreased expression of GK in liver in human type-2 diabetes [12]. On the other hand, animal models which overexpress GK in their hepatic tissues, showed a good glucose tolerance and an increase in hepatic uptake of glucose [32-35]. Our results regarding GK expression level and activity in mice liver tissues indicated high mRNA expression level and activity in diabetic-insulin treated and in diabetic mushrooms fed ones if compared with their control groups. The ability of the two types of mushrooms used in our experiment to increase the activity of GK and its expression level in hepatic tissues explained the ability of mushrooms to induce glucose uptake by liver for subsequent metabolism [35]. The matter induces lowering of blood glucose.

*In conclusion* our study revealed that mushrooms are a potent source of high nutritional value as it keeps body weight constant during the time of the experiment. Both types of mushrooms have the ability to increase hepatic glycogen contents and activate GK activity in STZ-diabetic mice, so Oyster and Button mushrooms have a potent hypoglycemic effect which enables them to be a new prospect for the control of diabetes.

*Acknowledgment:* This work was carried out in Biochemistry labs of veterinary medicine and Medicine faculty, Zagazig University under the supervision of Prof. Yousef M Shehata and Prof. Youssri M Hussein. Authors are thankful for help of Dr Rasha Etewa in preparing the manuscript.

## REFERENCES

- 1-Jeong SC, Jeong YT, Yang BK, Islam R, Koyyalamudi SR, et al. White button mushroom (*Agaricus bisporus*) lowers blood glucose and cholesterol levels in diabetic and hyper-cholesterolemic rats. *Nutrition Research*.2010; 30:pp.49–56.
- 2-Dundar A, Acay H, Yildiz A. Yield performances and nutritional contents of three oyster mushroom species cultivated on wheat stalk. *Afr J Biotechnol*.2008; 7:pp.3497–501.
- 3-Stengler M. *The Health Benefits of Medicinal Mushrooms*.2005. California: Basic Health Publications, Inc.
- 4-Fukushima M, Nakano M, Morii Y, Ohashi T, Fujiwara Y, et al. Hepatic LDL receptor mRNA in rats is increased by dietary mushroom (*Agaricus bisporus*) fiber and sugar beet fiber. *J Nutr*. 2000; 130:pp.2151-6.
- 5-Koyyalamudi SR, Jeong SC, Cho KY, Pang G. Vitamin B12 is the active corrinoid produced in cultivated white button mushrooms (*Agaricus bisporus*). *J Agric Food Chem*.2009;57:pp.6327-6333.
- 6- Koyyalamudi SR, Jeong SC, Song CH, Cho KY, Pang G. Vitamin D2 formation and bioavailability from *Agaricus bisporus* button mushrooms treated with ultraviolet irradiation. *J Agric Food Chem*.2009; 57: pp.3351-3355.
- 7- Mattila P, Könkö K, Eurola M, Pihlava JM, Astola J, et al. Contents of vitamins, mineral elements, and some phenolic compounds in cultivated mushrooms. *J Agric Food Chem*.2001; 49: pp.2343-2348.
- 8- Han C, Liu T. A Comparison of Hypoglycemic Activity of Three Species of Basidiomycetes Rich in Vanadium. *Biol Trace Elem Res*.2009; 127:pp.177-182.
- 9- Lv Y, Han L, Chao Y, Guo J. Comparison of Hypoglycemic Activity of Trace Elements Absorbed in Fermented Mushroom of *Coprinus comatus*. *Biol Trace Elem Res*.2009; 10:pp.8352-8357.
- 10-Aiston S, Trinh KY, Lange AJ, Newgard CB, Agius L. Glucose-6-phosphatase over expression lowers glucose 6-phosphate and inhibits glycogen synthesis and glycolysis in hepatocytes without affecting glucokinase translocation. Evidence against feedback inhibition of glucokinase. *The Journal of Biological Chemistry*. 1999; 274: pp.24559–24566.
- 11- Pal M. Medicinal chemistry approaches for glucokinase activation to treat type 2 diabetes. *Curr Med Chem*.2009;16:pp.3858-3874.
- 12- Caro JF, Triester S, Patel VK, Tapscott EB, Frazier NL, et al. Liver glucokinase: decreased activity in patients with type II diabetes. *Hormone and Metabolic Research*. 1995; 27: pp.19–22.
- 13- Ito M, Kondo Y, Nakatani A, Hayashi K, Naruse A. Characterization of low dose streptozotocin-induced progressive diabetes in mice. *Environmental Toxicology and Pharmacology*. 2001; 9:pp.71–78.
- 14-Minshal-Brown EP, Al Rabesi Z, Shahin A, Al-Shamsi M, Arsenijevic N, et al. Targeted disruption of the galectin-3 gene results in decreased susceptibility to multiple low dose streptozotocin-induced diabetes in mice. *Clinical Immunology*.2009; 130: pp.83–88.
- 15- Lee MY, Kong HJ, Cheong J. Regulation of activating transcription factor-2 in early stage of the adipocyte differentiation program. *Biochem Biophys Res Commun*.2001; 281:pp.1241–1247.
- 16- Walde SG, Velu V, Jyothirmayi T, Math RG. Effects of pretreatments and drying methods on dehydration of mushroom. *Journal of Food Engineering*.2006; 74:pp.108–115.
- 17-Sirag HM. Biochemical and Hematological studies for protective effect of Oyster mushroom (*pleurotus ostreatus*) against Glycerol-induced acute renal failure in rats. *Journal of Biological sciences*.2009; 9: pp.746-752.
- 18- Trinder P. Estimation of blood glucose by enzymatic method. *Ann. Clin. Biochem*.1969; 6:pp.24–28.
- 19-Roehring KL, Allred JB. Direct Enzymatic Procedure for the Determination of Liver Glycogen. *Analytical Biochemistry*.1974; 58: pp.414-421.
- 20-Pakoskey AM, Leshner EC, Scott DB. Hexokinase of *Escherichia coli*. Assay of enzyme activity and adaptation to growth in various media. *J. Gen. Microbiol*.1965 38:pp.73-80.
- 21- Jackerott M, Baudry A, Bucchini D, Jami J, Joshi RL. Improved metabolic disorders of insulin receptor-deficient mice by transgenic over expression of glucokinase in the liver. *Diabetologia*.2002; 45:1292–1297.
- 22- Uchida K, Kaneko T, Miyazaki H, Hasegawa S, irano T. Excellent salinity tolerance of Mozambique tilapia (*Oreochromis mossambicus*): Elevated chloride cell activity in the branchial and opercular epithelia of the fish adapted to concentrated seawater. *Zoo Sci*.2000; 17: pp.149-160.
- 23-Neyrinch AM, Bindels LB, De Backer F, Pachikian BD, Cani PD, et al. Dietary supplementation with chitosan derived from mushrooms changes adipocytokine profile in diet-induced obese mice, a phenomenon linked to its lipid-lowering action. *International Immunopharmacology*.2009; 9: pp.767-773.
- 24-Stutz DSH, Rosalia R, Destefanis VF, Fan L, Lucia TA, et al. Kidney Function Indices in Mice after Long Intake of *Agaricus brasiliensis* Mycelia (= *Agaricus blazei*, *Agaricus subrufescens*) Produced by Solid State Cultivation. *On line Journal of Biological Sciences*.2009; 9: pp.21-28.
- 25-Cho EJ, Hwang HJ, Kim SW, Oh JY, Baek YM, et al. Hypoglycemic effects of exo polysaccharides produced by mycelial cultures of two different mushrooms *Tremella fuciformis* and *Phellinus baumii* in ob/ob mice. *Appl Microbiol Biotechnol*.2007; 75:pp.1257–1265.
- 26-Hwang HJ, Kim SW, Lim JM, Joo JH, Kim HO, et al. Hypoglycemic effect of crude exopolysaccharides produced by a medicinal mushroom *Phellinus baumii* in streptozotocin- induced diabetic rats. *Life Sci*.2005; 76:pp.3069–3080.
- 27-Kim DH, Yang BK, Hur NJ, Das S, Yun JW, et al. Hypoglycemic effects of mycelia produced from a submerged culture of *Phellinus linteus* (Berk. et Curt) Teng (*Aphyllphoromycetidae*) in streptozotocin induced diabetic rats. *International Journal of Medicinal Mushrooms*.2001; 3: pp.21–26.
- 28-de Abreu LA, Fabres A, Esteves E, Masuda A, da Silva V, et al. Exogenous insulin stimulates glycogen accumulation in *Rhipicephalus (Boophilus) microplus* embryo cell line BME26 via PI3K/AKT pathway. *Comparative Biochemistry and Physiology*.2009; Part B 153: pp.185–190.
- 29-Zhou G, Han C. The Co-effect of Vanadium and Fermented Mushroom of *Coprinus comatus* on Glycaemic Metabolism. *Biol Trace Elem Res*.2008; 124:pp.20–27.
- 30-Yang BK, Kim DH, Jeong SC, Das S, Choi YS, et al. Hypoglycemic effect of a *Lentinus edodes* exopolymer produced from a submerged mycelial culture. *Biosci Biotechnol Biochem*.2002; 66:pp.937–942.
- 31-Matschinsky FM, Magnuson MA, Zelent D, Jetton TL, Doliba N, et al. The network of glucokinase-expressing cells in glucose homeostasis and the potential of glucokinase activators for diabetes therapy. *Diabetes*.2006; 55:pp.1–12.
- 32-Zelent D, Najafi H, Odili S, Buettger C, Weik-Collins H, et al. Glucokinase and glucose homeostasis: proven concepts and new ideas. *Biochemical Society Transactions*.2005; 33: pp.306–310.
- 33- Ferre T, Riu E, Bosch F, Valera A. Evidence from transgenic mice that glucokinase is rate limiting for glucose utilization in the liver. *FASEB J*.1996; 10:pp.1213-1218.
- 34-Niswender K, Postic C, Jetton TL, Bennett BD, Piston DW, Efrat S, Magnuson MA. Cell-specific expression and regulation of a glucokinase gene locus transgene. *J Biol Chem*.1997; 272: pp.22564-22569.

35-Shiota M, Postic C, Fujimoto Y, Jetton TL, Dixon K, et al. Glucokinase gene locus transgenic mice are resistant to the development of obesity-induced type 2 diabetes. *Diabetes*.2001; 50: pp.622-629.

Table I: The effect of mushrooms: Oyster (*Pleurotus ostreatus*), Button (*Agaricus bisporus*) feeding and insulin treatment on fasting blood glucose level (mg/dL), hepatic glycogen content (mg/gm tissue), and hepatic glucokinase activity (U/L) in STZ- induced diabetic mice.

Parameters	Duration	Control group	Insulin-treated	Oyster-treated	Button-treated
Blood glucose (mg/dL)	30 days	118.71± 6.26c	98.28± 8.22de	143.71± 10.76c	140.57± 12.31c
	60 days	116.20± 15.76ab	83.57± 11.13e	97.00± 4.69d	96.71± 6.26f
Hepatic glycogen (mg/gm tissue)	30 days	21.14± 1.40bc	21.82± 1.89bc	17.34± 1.19cd	13.85± 0.73d
	60 days	25.58± 4.21b	41.08± 7.66a	38.38± 2.96a	39.10± 9.13a
Hepatic glucokinase activity(U/L)	30 days	61.79± 3.26e	104.25± 3.24b	59.18± 4.70e	44.76± 8.73f
	60 days	81.01± 3.3d	98.38± 5.77c	117.66± 2.28a	95.08± 3.46c

Means within the same column carrying different superscripts are significant at (P <0.05)



Figure 3: Effect of Mushrooms; Oyster (*Pleurotus ostreatus*), Button (*Agaricus bisporus*) feeding and insulin treatment GK gene expression in liver tissues of STZ-induced diabetic mice and control group.



Figure 4: Expression level of GAPDH as a house keeping gene in liver tissues of mice and control group.

1: Control group for 30 days; 2: Control group for 60 days; 3: Insulin treated group for 30 days; 4: Insulin treated group for 60 days; 5: Oyster fed group for 30 days; 6: Oyster fed group for 60 days; 7: Button fed group for 30 days; 8: Button fed group for 60 days; M: 100 bp Molecular marker.




Figure 1: Effect of Mushrooms; Oyster (*Pleurotus ostreatus*), Button (*Agaricus bisporus*) feeding and insulin treatment on fasting blood glucose (mg/dL) in STZ- induced diabetic mice.




Figure 2: Effect of Mushrooms; Oyster (*Pleurotus ostreatus*), Button (*Agaricus bisporus*) feeding and insulin treatment on hepatic glycogen level (mg/gm tissue) in STZ- induced diabetic mice and control mice.